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Introduction and Aims: Autosomal dominant polycystic kidney disease (ADPKD) is
the most common inherited renal disease. It accounts 5% of the patients with end stage
renal disease (ESRD). Despite the fact that numerous treatment options are likely
becoming available in the near future, predicting disease course would be of utmost
importance to select high-risk patients for treatment. Up to now, we identified
ADPKD-specific peptide markers that distinguish ADPKD patients from healthy state
as well as patients with other renal diseases. In this study, we aimed to identify urinary
peptide marker panel associated with future progression towards ESRD in ADPKD
patients with an extended follow up time of 13 years. This work is supported by
TranCYST and iMODE-CKD grant projects.
Methods:We used capillary electrophoresis online coupled with mass spectrometry to
analyze the low molecular weight urinary proteome (0.8-20 kDa) of 14 ADPKD
patients with progression to ESRD and 39 ADPKD patients with slow disease
progression (as defined as a mGFR and eGFR slope of not more than -3 ml/min/
1.73m2/year) over a follow up period of 13 years to establish a ESRD-predictive urinary
peptide marker model.
Results: A multidimensional marker model established in training cohort consisting of
16 urinary peptides enabled the prediction of ESRD in an independent cohort of
ADPKD patients (n=19; 5 reaching ESRD excluding those with age above 40 years at
baseline and 14 without ESRD during follow up with age less than 24 at baseline) with
an area under the curve value of 0.94 (less than 0.0001) and a 95% confidence interval
ranging from 0.73 to 0.99 in receiver operating characteristic analysis. Sensitivity and
specificity was 80% and 71% at the predetermined cut-off level of above -0.64. For
further validation, we applied the proteomic model to young ADPKD patients (less
than 24 years of age) to predict their progression to ESRD (i.e GFR change from
baseline to year 8). In this group, the model showed a reasonable correlation with GFR
slope (R2=0.29).
Conclusions: In our discovery and validation study, we identified urinary peptide
markers that enabled prediction of ESRD in ADPKD patients with a prognostic
accuracy similar to that of total kidney volume.
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